ArticleScientific reports2025
Upregulation of long non-coding RNA SNHG11 promotes apoptosis and its molecular mechanisms in human osteosarcoma U2OS cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a malignant bone tumor of mesenchymal origin, which is common in children and adolescents. Long non-coding RNA (lncRNA) SNHG11 plays important regulatory roles in various cancers, particularly in promoting cell migration, invasion, and proliferation. However, the function and regulatory mechanisms of SNHG11 in osteosarcoma remain unclear. In this study, we found that overexpression of SNHG11 in human osteosarcoma U2OS cells significantly inhibited cell proliferation and promoted apoptosis. Overexpression of SNHG11 in U2OS cells resulted in significant differential expression of 344 genes, including 82 upregulated genes and 262 downregulated genes. The upregulated genes were not significantly enriched in GO-P, although HMGCS2 and IL24 may play important roles. The downregulated genes were significantly enriched in GO-P related to cell adhesion and migration, with key genes including KRT17, CXCL14, TRIB2, COL5A1, CCL24, SOX2, and COL6A3.SNHG11 may interact with KRT6B, SERPINB12, and DCD proteins to regulate downstream targets. ChIRP-seq (RNA) sequencing revealed that SNHG11 specifically binds to EEF2, RPS4X, and ACTG1. ChIRP-seq (DNA) sequencing showed that SNHG11 gene was mainly enriched in biological processes such as negative regulation of apoptosis. Integrated analysis of ChIRP-seq (RNA) revealed 32 overlapping genes, suggesting that SNHG11 may contribute to osteosarcoma progression by binding to DCD and regulating these targets. Similarly, ChIRP-seq (DNA) analysis identified 16 overlapping genes. Combined with protein profiling data, we speculate that SNHG11 may be involved in osteosarcoma progression by binding to SERPINB12 and regulating transcription. In conclusion, lncRNA SNHG11 plays a critical role in osteosarcoma development by regulating cellular information carriers at the DNA, RNA, and protein levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.